治疗肝胆癌：免疫治疗方法。
Treating Hepatobiliary Cancer: The Immunologic Approach.
作者信息
Duffy A G, Greten T F
机构信息
Gastrointestinal Malignancies Section, Thoracic-GI Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
出版信息
Dig Dis. 2017;35(4):390-396. doi: 10.1159/000456593. Epub 2017 May 3.
Hepatobiliary cancer comprises a heterogeneous group of malignancies in which the standard treatments for advanced disease are minimally effective and evolve slowly over time. Like the majority of gastrointestinal cancers, with some notable exceptions, the impact of immune-based approaches is yet to be experienced. Notwithstanding this, the etiological background of hepatobiliary cancer - overlapping in almost every known causative or associated factor with inflammation - provides a strong clue that these approaches may have an impact on this group of diseases. This review seeks to put the management of hepatobiliary cancers in the context of its inflammation-based etiology, with the aim of pointing to the therapeutic opportunities in immune-based approaches currently entering the clinic or those that are about to do so.
肝胆癌是一组异质性恶性肿瘤，其中晚期疾病的标准治疗效果甚微，且随着时间推移进展缓慢。与大多数胃肠道癌症一样，除了一些显著的例外情况，基于免疫的治疗方法的影响尚未显现。尽管如此，肝胆癌的病因背景——几乎在每一个已知的致病或相关因素中都与炎症重叠——有力地表明这些方法可能对这组疾病产生影响。本综述旨在将肝胆癌的治疗置于其基于炎症的病因背景下，目的是指出目前正在进入临床或即将进入临床的基于免疫的治疗方法中的治疗机会。
Zotero 插件